RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models

Table 2 Inhibition of RT-SHIV replication by antiretroviral compounds

Drugs Category	Anti-HIV drugs	EC₅₀ (μM)	CC₅₀ (μM)	Selectivity index(SI)
NNRTIs	Efavirenz	0.002 ± 0.001	35.72 ± 25.45	17860
	Nevirapine	0.06 ± 0.01	> 100	> 1667
	UC781	0.003 ± 0.002	59.22 ± 6.56	19740
NRTIs	ZIdovudine (AZT)	0.01 ± 0.01	> 100	> 10000
	Lamivudine (3TC)	0.43 ± 0.13	> 100	> 233
	Stavudine (D4T)	0.01 ± 0.01	66.48 ± 34.84	6648
	Emtricitabine (FTC)	0.1 ± 0.1	> 100	> 1000
	Tenofovir	0.82 ± 0.62	> 100	> 122
PIs	Ritonavir	0.1 ± 0.1	63.92 ± 43.03	639
	Indinavir	0.008 ± 0.008	> 100	> 12500
	Saquinavir	0.004 ± 0.007	62.18 ± 32.75	15545

NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside RT inhibitors;
PIs: protease inhibitors
EC₅₀: Effective concentration of antiretroviral drug inhibited 50% virus replication.
CC₅₀: Cytotoxic concentration of antiretroviral drug showed cytotoxic effect in 50% of cells.
SI: selectivity index represents a ratio of CC₅₀ to EC₅₀.

ISSN: 1742-6405